Kornimate/medical-research-clean huggingface dataset:
investigation of musculoskeletal system disorders seen in automotive industry workers

Conditions: Work-related Illness; Work Injury

Summary: the aim of this study is to examine the musculoskeletal disorders seen in automotive industry workers.

this study will be conducted as a face-to-face survey. surveys will be created with google forms and will be filled out by the physiotherapist according to the participant's response.

Eligibility criteria:
inclusion criteria: * being between the ages of 25-60 * not having any psychological or neurological disorders * being able to communicate in turkish (written, verbal) * being able to communicate cognitively adequately * working full-time * being employed in an automotive industry for at least 5 years exclusion criteria: * being under 18 or over 60 * working part-time * being employed in the same business for less than 5 years
adjunctive photodynamic therapy in the treatment of chronic periodontitis

Conditions: Chronic Periodontitis

Summary: the aim of this randomized clinical trial is to clinically evaluate the effectiveness of the adjunctive use of photodynamic therapy (pdt) with an light-emitting diode (led) light source in the treatment of chronic periodontitis.


Eligibility criteria:
inclusion criteria: 1. clinically diagnosis of advanced chronic periodontitis with more than 3 mm clinical attachment loss 2. presence of at least two teeth with probing depth of 4 to 6 mm without furcation involvement in each quadrant 3. at least 16 remaining teeth 4. no periodontal treatment in the past 12 months 5. no evidence of systemic disease related to periodontal problems 6. no use of antibiotics for the past 6 months 7. no smoking more than 10 cigarettes per day 8. no addiction to any kind of drugs 9. no pregnancy

Keywords: photodynamic therapy light-emitting diode toluidine blue scaling and root planing
combination bisphosphonate and anti-angiogenesis therapy with pamidronate and thalidomide

Conditions: Multiple Myeloma

Summary: the purpose of this research is to study how helpful the combination of thalidomide and pamidronate or thalidomide and zometa is in controlling the myeloma disease and to study any side effects.

recently laboratory research found that thalidomide can inhibit the formation of new blood vessels that are necessary for the growth and spread of cancer. in order to grow and increase in size tumors require new blood vessels to supply them with the necessary blood to grow. if we can prevent these new blood vessels feeding the tumor from being formed by using thalidomide we might slow or stop the growth of the tumor. this concept is called "anti-angiogenesis" it is hoped that thalidomide will slow or stop the growth myeloma. however, it cannot be guaranteed that you will benefit if you take part in this study. the treatment you receive may even be harmful.

Eligibility criteria:
inclusion criteria: * patients must have a diagnosis of smoldering or indolent myeloma * all patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with uams human research advisory committee and federal guidelines. exclusion criteria: * prior bisphosphonate therapy within 30 days prior to study entry. * serum creatinine \> 5 mg/dl, ascites, or serum direct bilirubin \> 2.5 mg/dl. * prior plicamycin or calcitonin within 2 weeks of study entry. * severe cardiac disease, unstable thyroid disease, or epilepsy. * prior radiation therapy to \> 20% of the skeleton.

Keywords: myeloma thalidomide pamidronate aredia bisphosphonate anti-angiogenesis smoldering/indolent myeloma zometa
effect of high altitude exposure, acclimatization and re-exposure on postural control in lowlanders

Conditions: Effect of High Altitude

Summary: prospective interventional trial in lowlanders evaluating the effect of acute exposure, acclimatization and re-exposure to high altitude on postural control

baseline measurements including the assessment of the center of pressure during 30s, the cerebral oxygen saturation and a sharpened romberg test will be performed in santiago de chile, 520 m, over the course of 3 days. participants will then travel by commercial airline (5 h flight) and by bus (3 h ride) to the base camp of the atacama large millimeter/submillimeter array (alma) telescope station located at 2900 m near san pedro de atacama, northern chile. participants will stay there for the next 8 nights and they will be spend the days (6-8 h daily) at the telescope station at 5050 m while undergoing testing as described above at the first and the last day at 5050m. daily transports from 2900 to 5050 m will be by car (1 h ride, one way). after the first 8 day altitude sojourn participants will return to the santiago area (520 m) for a 6 day recovery period. a second altitude sojourn with an identical schedule as the one described above and a final low altitude stay of 3 days will follow.

Eligibility criteria:
inclusion criteria: * born, raised and currently living \<800m * no overnight stay at altitudes \>1500 m 4 weeks before the study exclusion criteria: * previous altitude intolerance to altitude \<3000 m * pregnancy * health impairment, which requires regular treatment

Keywords: postural control high altitude
thoracic fluid content by electrical cardiometry versus lung ultrasound in mechanically ventilated patients

Conditions: Thoracic Fluid Content; Electrical Cardiometry; Lung Ultrasound; Mechanical Ventilation; Intensive Care Unit

Summary: this study aims to compare the accuracy of the total thoracic fluid content (tfc) measured by electrical cardiometry with accuracy of lung ultrasound score in prediction of weaning outcome in mechanically ventilated patients.

weaning of patients from mechanical ventilation remains one of the critical decisions in the intensive care unit. earlier patient weaning from mechanical ventilation is recommended to avoid complications of prolonged mechanical ventilation; however, premature weaning might result in extubation failure which is, independently, associated with poor outcomes. screening for eligibility is the first step in the weaning process, followed by the spontaneous breathing trial (sbt). various indices should be checked carefully before starting a spontaneous breathing trial to ensure adequate oxygenation, ventilation, and airway reflexes. however, nearly one-third of patients fail and are reintubated despite fulfillment of all the current weaning pre-requisites.

Eligibility criteria:
inclusion criteria: * 85 mechanically ventilated patients for ≥ 48 hours * aged 18-65 years * both sex * fulfilled the weaning readiness criteria * scheduled for spontaneous breathing trial (sbt) using pressure support ventilation. exclusion criteria: * acute respiratory distress syndrome (ards) patients. * interstitial lung fibrosis. * patients with lung resection. * pulmonary embolism. * patients with fluid overload due to heart, renal or hepatic failure. * cardiac patients with ejection fraction less than 40%, cardiomyopathy, congenital or valvular heart diseases. * pneumothorax. * pleural or pericardial effusion. * pregnancy. * patients with injuries, burns, or wounds which precluded the proper application of the device electrodes or the ultrasound transducer.
invitro maturation of oocytes for patients with polycystic ovaries

Conditions: Infertility; Polycystic Ovaries

Summary: in vitro maturation of oocytes after minimal gonadotropin stimulation in patients with polycystic ovaries, to prevent cases of ovarian hyperstimulation.


Eligibility criteria:
inclusion criteria: * polycystic ovaries * needing ivf for fertility treatment exclusion criteria: * age above 39

Keywords: in vitro maturation oocytes
a study to assess the efficacy of risankizumab compared to fumaderm® in subjects with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy

Conditions: Psoriasis

Summary: the purpose of this study is to compare the efficacy and safety of subcutaneous (sc) risankizumab and oral fumaderm provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy.

the efficacy analysis was performed in the intent to treat (itt) set which included all participants who were randomized. the safety analysis was performed in the safety set which included all participants who received at least one dose of study drug. no participants were excluded from the efficacy analysis. three participants in the fumaderm® group discontinued after randomization prior to receiving any study drug and were thus not included in the safety set.

Eligibility criteria:
inclusion criteria: * have a diagnosis of chronic plaque psoriasis for at least 6 months before the first administration of study drug. duration since diagnosis may be reported by the participant * participant has stable moderate to severe plaque psoriasis (body surface area \[bsa\] \>10, psoriasis area and severity index \[pasi\] \>10, and dermatology quality of life index \[dlqi\] \>10) with or without psoriatic arthritis at baseline * must be naïve to and candidate for systemic therapy, as assessed by the investigator * participant has an inadequate response, intolerance or contraindication to topical psoriasis treatment exclusion criteria: * participants with non-plaque forms of psoriasis * participant has previously received systemic therapy for psoriasis, whether biologic or non-biologic or photochemotherapy * active systemic infection during the last 2 weeks (exception: common cold) prior to screening. * any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix * participant has any condition or contraindication to fumaderm that would preclude the patient's participation in the present study

Keywords: abbv-0066 bi 655066 risankizumab
a brief mind-body bridging intervention for suicidal ideation

Conditions: Suicidal Ideation; Mind Body Bridging

Summary: the aim of this study is to determine whether a brief mind-body bridging intervention for suicidal ideation (mbb-si) will result in short or longer-term reduction of psychological factors associated with suicidal ideation (si) and/or suicide-related behaviors (srb's) compared to treatment as usual (tau).


Eligibility criteria:
inclusion criteria: * subjects will be veterans aged 18-80 admitted to substance abuse residential rehabilitation treatment program (sarrtp) with addictive disorders and/or co-occurring psychiatric disorder with suicide risk factors. exclusion criteria: * none

Keywords: mind body bridging mindfulness suicidal ideation suicide related behaviors
data collection for prediction of postoperative chronic pain for a software

Conditions: Chronic Postoperative Pain

Summary: postoperative persistent pain (ppp) is reported with a high incidence in adults 11.5-47%. this high incidence effects quality of life of patients causes social-economical problems and arises medico-legal issues. this study will be undertaken for producing a database by the evaluation of surgeries in 4 hospitals located in istanbul. this database will be used in establishing a software by using data mining technology in the prediction of ppp

all cases operated in 4 different hospitals in one month period will be included exclusion criteria: cases who could not be followed up to 2 months postoperatively by telephone call. a questionnaire will be filled preoperatively for each case after obtaining informed case . all cases will be anesthetized and pain therapy will be applied according to anesthesiologist's own practice and pain relief will be evaluated and noted. all patients will be telephoned postoperatively for the pain level at 15,30,45 and 60th day. all the information will be uploaded to computer and a software will be prepared for prediction of postoperative chronic pain.

Eligibility criteria:
inclusion criteria: * all cases operated in one month period exclusion criteria: * cases who cannot be followed for 2 months

Keywords: postoperative chronic pain software
liquid biopsy to predict responses to first-line immunotherapy in metastatic non-small cell lung cancer. liberty lung

Conditions: Metastatic Lung Cancer

Summary: patient with histologically proven nsclc in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. combination with chemotherapy is possible. presence of a mutation after ngs analysis is required for ctdna follow-up.

a pre-screening consent will be obtained for ngs analysis on tumor tissue. only patients with at least 1 mutation at ngs on the tumor tissue will ultimately be enrolled in the study, to have the possibility to follow the mutation using ctdna. main consent will be obtained after results of the ngs and before initiation of pembrolizumab. computed tomography (ct)-scan imaging will be done every 9 weeks as part of routine care practice. blood specimens will be taken with edta tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks. blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 week. an additional measurement will be performed if treatment is stopped before the end of the study. - optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes.

Eligibility criteria:
inclusion criteria: 1. histologically-proven nsclc. 2. age ≥ 18 years. 3. advanced or metastatic stage iv. 4. treatment-naïve patient. 5. eligibility to first-line treatment with immune checkpoint inhibitor. 6. measurable disease according to recist 1.1 criteria on ct-scan. 7. availability of expression of pd-l1 at immunohistochemistry analysis of the tumor biopsy. 8. no alk or egfr gene alteration. 9. availability of tumor tissue for ngs analysis (7 slides). 10. ps 0 or 1. 11. signed informed consent of the patient. exclusion criteria: 1. no social security affiliation. 2. person under legal protection. 3. pregnant and breastfeeding women. patients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy/chemotherapy treatment nor study follow-up ; after investigator's information

Keywords: lung cancer nsclc metastatic stage first-line treatment with immunotherapy
seeing-moving-playing: early rehabilitation utilizing visual and vestibular technology following traumatic brain injury

Conditions: Mild Traumatic Brain Injury; Concussion

Summary: the aim of this research program is to 1) evaluate potential problems with vision, inner ear-eye reflexes and deficits of processing eye information that occur following tbi; and 2) evaluate treatment programs for individuals with eye and inner ear problems that persist for greater than 10 days following injury. this study will include 465 youth and young adults (aged 6-30 years old) who sustain a tbi of any severity. an initial evaluative phase using the best available technology to evaluate eye and inner ear function will be performed, and compared with typical tests that are used in the clinic. if symptoms and functional problems remain 10 days after injury, participants will be randomly placed into a treatment group (including eye movement, inner ear-eye reflex and attention exercises as per our pilot studies) or a control group (typical rehabilitation). success will be measured in terms of return to sport (mild tbi), achievement of goals (moderate and severe tbi) and quality of life. it is expected that this program will inform clinical practice and future research leading to a treatment program in tbi that includes multiple components.


Eligibility criteria:
inclusion criteria: * mild tbi or moderate-severe tbi will be included exclusion criteria: -
comparison of the therapeutic effects of vaginal repair with leuprorelin and vaginal repair in the treatment of cesarean section scar defect

Conditions: Cesarean Section; Dehiscence

Summary: gnrh-a will be used to postpone period after vaginal repair for cesarean section scar defect（csd） patients with adenomyosis which will be compared with csd patients with adenomyosis who receive transvaginal surgery without gnrh-a, whether delayed period improving the csd prognosis will be assessed.

women with csd complicated with adenomyosis will be enrolled in this study. they all will receive vaginal excision and suture of csd and will be required to undergo examinations at 6-months after surgery. interventioned group will be subcutaneous injected of leuprorelin to postpone period after vaginal repair. it is be assumed that temporary menopause could improve inner conditions of uterus, there would be less local inflammation reaction which would be beneficial to the scar healed.

Eligibility criteria:
inclusion criteria: 1. clearly diagnosed with csd complicated with adenomyosis 2. experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days). 3. the thickness of the remaining muscular layer of csd was less than 3 mm. 4. normal range of blood sugar and insulin 5. no serious medical problems (important viscera function in the normal range). 6. uterine fibroids no more than 5cm 7. sign the informed consent. exclusion criteria: 1. indefinite diagnosis. 2. malignant tumors. 3. with severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs). 4. pregnant. 5. mental diseases. 6. allergy to the any ingredients of leuprorelin 7. unwilling to comply with the research plan.

Keywords: cesarean section scar defect zoladex vaginal repair
ultrasound predictors of early pregnancy failure in patients with recurrent pregnancy loss

Conditions: Recurrent Pregnancy Loss; Early Pregnancy Failure

Summary: evaluation of the role of ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss

1. mean gestational sac diameter (msd) is determined by measuring the mean of 3 diameters (longitudinal, antero-posterior and transverse) which are measured from inside of the sac excluding the decidual reaction from the measurement. it is normally eccentric in location embedded in endometrium, and has a smooth; round or oval shape. 2. yolk sac is measured by placing calipers on the inner limits of the longer diameter. it usually appears at the periphery of the gestational sac and should not be floating within the sac. size of the sac, shape, echogenicity of the rim and center of sac, its number and degenerative changes such as calcification will be evaluated. ys having diameter between 3-7mm, rounded shape, absence of degenerative changes, presence of echogenic rim and hypoechoic center are considered normal. any deviation from above parameters is considered abnormal. 3. crown-rump length (crl) is the length of the embryo from the top of its head to bottom of torso excluding the yolk sac and the extremities, to be measured in sagittal plane of the embryo and recorded as an average of three measurements. 4. the mgsd-crl ratio was calculated as the difference between the mgsd and the crl if less than 5 mm are prone to first trimester miscarriage. 5. embryonic heart rate by m-mode calculated as beat per minute using software of ultrasound machine after measuring by electronic calibers of distance between 2 heart waves on frozen m-mode image. 6. uterine artery doppler with measurement of systolic/diastolic (s/d) ratio, resistance index (ri) and pulsatility index (pi) of uterine arteries.

Eligibility criteria:
inclusion criteria: * a positive pregnancy test result. * single intrauterine pregnancy. * gestational age by last menstrual period of 6-10 weeks in patients with regular cycles and sure of her last menstrual period date. * history of recurrent pregnancy loss which is defined as three or more consecutive pregnancy losses. exclusion criteria: * women who are uncertain of her last menstrual period date. * women with irregular menstrual cycles. * multiple pregnancies
identification of modifying factors in hereditary spastic paraplegia

Conditions: Hereditary Spastic Paraplegia

Summary: a first questionnaire - modifspa conducted in 2014 - identified several environmental factors influencing spasticity in hsp: cold, fatigue, and especially physical activity. in order to improve the care of patients with hsp, the investigator team are looking to deepen the knowledge on physical exercises relieving spasticity as well as to better know the frequency of symptoms requiring additional medical care: fatigue and vesico-sphincter disorders. a new questionnaire was therefore created to collect additional information to optimize the care of patients with hsp.

the only common symptom of hereditary spastic paraplegia (hsp) is the presence of spasticity in the lower limbs, associated with a great clinical and genetic heterogeneity. a first modifspa study carried out by the team identified environmental factors influencing spasticity: stress, fatigue, physical activity. in this first study, only spasticity was studied but several symptoms appeared to require medical management according to the patients: fatigue and vesico-sphincter disorders. following this first study, modifspa2 aims to deepen our knowledge of hsp, via the expertise of patients, to propose a care in adequacy with their needs/demands. validated scales are included in the questionnaire to evaluate the frequency and intensity of the symptoms most reported by patients (fatigue, pain and mood disorders). questions are asked to better know the frequency of symptoms requiring additional medical care: fatigue and vesico-sphincter disorders.

Eligibility criteria:
inclusion criteria: * french-speaking adult patients aware of their psh diagnosis coming to the genetic consultation at the pitié-salpêtrière hospital or informed via an association / website of the brainteam study network * affiliated with social security exclusion criteria: * na
fusobacterium nucleatum at colorectal cancer sites

Conditions: Colorectal Cancer; Periodontitis

Summary: recent studies suggest an association of periodontitis with an overall increased cancer risk but also with cancer development in specific anatomic regions, such as in the colon. the gut microbiome in general and specifically fusobacterium nucleatum have been described to likely affect colorectal cancer (crc) development. the present project intends to evaluate the possible contribution of the oral cavity as a reservoir for dissemination of f.nucleatum to the colon. additionally, the gut microbiome and dietary intake will be assessed as possible factors influencing colonization of crc sites with f. nucleatum and an association of f.nucleatum colonization in the colon with parameters in the saliva and serum will be tested. one-hundred-fifty patients diagnosed with crc will be included; after cancer diagnosis and before starting cancer treatment a periodontal examination will be done and saliva and serum samples and at the time-point of tumor resection a biopsy of the crc sites will be collected.


Eligibility criteria:
inclusion criteria: * diagnosis of colorectal cancer